Multiple myeloma (MM) is typically sensitive to a range of cytotoxic agents, both as initial therapy and as relapsed disease treatment. Unfortunately, the responses are transient, and MM is not considered curable with the current approaches. This paper aims to assess the response to first line treatment of patients included in the study and their correlation with the negative prognostic factors in multiple myeloma: age over 60 years, male gender, anemia, hypercalcemia, elevated levels of creatinine, Beta 2 microglobulin, hypoalbuminemia and Bence-Jones proteins type. The study was conducted on a group of 105 patients admitted to the Hematology Department of the Municipal Emergency Clinical Hospital of Timisoara from 01 January 2013 until 31 December 2017. Twenty-seven patients received VAD regimen, while 78 underwent Bortezomib + Dexamethasone regimen as fist line therapy. When analyzing anthropometrical data, different gender distribution in the two groups of patients is seen, while a higher percentage of patients over 60 years is observed in both groups, with 77.7% in the VAD group (21 out of 27 patients) and 56.4% in the group treated with Bortezomib + Dexamethasone (44 out of 78 patients). Only some of the factors analyzed in our study statistically significantly influenced the response to treatment and the duration of survival, i.e.: age over 60 years, hemoglobin [10g/dL, platelets under 150000/mm3, creatinine ]2mg/dL, serum calcium ]10mg / dL, increased C-reactive protein, low serum albumin levels, high levels of Beta 2 microglobulin, total serum protein, as well as presence of cells in the peripheral smear. Defining a panel of negative prognostic factors that influence the evolution and response to multiple myeloma treatment would allow for tailoring of personalized therapies for each patient.
The Hodgkin lymphoma treatment is adapted to the disease type, disease stage and to an evaluation of the risk. The treatment is focused on the adjustment of the therapy to each patient depending on the age, toxicity risk on short and long term and the relapse risk. The study proposes the evaluation of the response to the treatment further to the administration of different therapeutic regimens as well as the correlation with the negative diagnosis factors of Hodgkin lymphoma. This is a retrospective study on 71 patients diagnosed with Hodgkin lymphoma in the Hematology Department of Timisoara between January 2014 and December 2017. The data obtained have been collected from a database and processed with the SPSS 20.0. software . In our study there were included 71 patients diagnosed with Hodgkin lymphoma with a medium age of 42.12�16.45 years old. By the time of the diagnosis, the patients showed the following hematological, biochemical and immunological parameters. The response to treatment is influenced by the presence of the negative prognosis factors : the age of �40 years old, extralymphatic infiltration, VSH ] 50mm/h , presence of general B signs, more than 3 lymph node sites affected, bulky disease and Ann-Arbor III and IV stages. The treatment of Hodgkin lymphoma is guided by the traditional clinic prognostic factors and by the laboratory which often represent a substitute marker for the biological characteristics which many times are not included in the standard evaluation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.